Clinical trials: Dual Antiplatelet Therapy
Type2 Diabetes Mellitus, Coronary Heart Disease
Anti-thrombotic and Glucose Lowering Therapy in Diabetic Patients Undergoing PCI
Diabetes mellitus (DM) is one of the main risk factors for ischemic events in patients with coronary artery disease (CAD) and diabetes is a factor in several post-PCI (Percutaneous Coronary Intervention) risk scores.
- Trial name
- ARTHEMIS (NCT04481997)
- Testing
- Exposure to Anti-thrombotic treatment agents and glucose lowering therapy
- Where
- 12 sites in Portugal
- Volunteers
- 1,000 people
- Sponsor
- Associacao para Investigacao e Desenvolvimento da Faculdade de Medicina - CETERA
Stable Angina
Safety and Efficacy Study of Endothelial Progenitor Cell Capture Stent With 1 Months Dual Antiplatelet Therapy
Thanks to rapid reendothelialization derived from the pro-healing property of the EPC capture stent, 1-month dual antiplatelet therapy (DAPT) is recommended after EPC capture stent implantation.
- Trial name
- INNOVATION (NCT01394848)
- Testing
- Endothelial cell capture stent with 1 month clopidogrel, Everolimus eluting stent with 12 month clopidogrel, Atorvastatin 20mg loading
- Where
- South Korea
- Volunteers
- 1 people
- Sponsor
- Yonsei University
Coronary Artery Disease, Coronary Artery Bypass Grafting
TOP-CABG Trial: Follow-up Extension (TOP-CABG FE)
To further evaluate the long-term effects of the two antiplatelet strategies on saphenous vein graft patency, long-term adverse cardiovascular events, and bleeding events after coronary artery bypass grafting (CABG), we plan to…
- Conditions
- Coronary Artery Disease, Coronary Artery Bypass Grafting, Dual Antiplatelet Therapy, Bleeding
- Trial name
- NCT07871591
- Volunteers
- 2,290 people
- Sponsor
- China National Center for Cardiovascular Diseases
ST Segment Elevation Myocardial Infarction
Anfibatide Treatment in STEMI Patients
A Phase IIb clinical trial to investigate the safety and efficacy of antiplatelet thrombolysin injection for patients with ST Segment Elevation Myocardial Infarction (STEMI) before receiving PCI therapy, in order to provide…
- Trial name
- NCT02495012
- Testing
- Anfibatide
- Where
- China
- Volunteers
- 240 people
- Sponsor
- Lee's Pharmaceutical Limited
Coronary Artery Disease
Synergy Between Stent and Drugs to Avoid Ischemic Recurrences After Percutaneous Coronary Intervention
The duration of dual antiplatelet treatment (i.e. asprin and clopidogrel) after drug-eluting stent implantation is highly debated.
- Trial name
- PRODIGY (NCT00611286)
- Testing
- clopidogrel treatment after bare metal stent implantation, clopidogrel after zotarolimus-eluting stent implantation, clopidogrel after paclitaxel-eluting stent implantation
- Where
- Italy
- Volunteers
- 1,700 people
- Sponsor
- Marco Valgimigli
Ischemic Heart Disease
DETErmination of the Duration of the Dual Antiplatelet Therapy by the Degree of the Coverage of The Struts on Optical Coherence Tomography From the Randomized Comparison Between Everolimus-eluting Stents(EES) Versus Biolimus A9-eluting Stents(BES)
The purpose of the study is 1> to compare neointimal stent coverage after OCT-guided vs. Angio-guided PCI, 2> to compare neointimal stent coverage at 3 months after EES vs BES implantation, 3> to determine the duration of dual…
- Trial name
- DETECT-OCT (NCT01752894)
- Testing
- Angio-guided PCI with EES or BES, OCT-guided PCI with EES or BES, PCI with BES under angio-guide or OCT guide
- Where
- South Korea
- Volunteers
- 776 people
- Sponsor
- Yonsei University
Acute Coronary Syndrome, Myocardial Infarction
Future Optimal Research and Care Evaluation
Rationale: Acute coronary syndrome (ACS) is the leading cause of death worldwide. To improve cardiovascular care, research is needed.
- Trial name
- FORCE-ACS (NCT03823547)
- Where
- 4 sites in Netherlands
- Volunteers
- 99,999 people
- Sponsor
- J.M. ten Berg
Chronic Coronary Disease
One-Month DAPT in CABG Patients
The purpose of this study is to compare the effect of ticagrelor plus low-dose aspirin versus low-dose aspirin alone in patients with chronic coronary disease undergoing coronary artery bypass grafting.
- Trial name
- ODIN (NCT05997693)
- Testing
- Ticagrelor 90 MG, Low-dose aspirin
- Where
- 22 sites in United States, Austria and 4 more
- Volunteers
- 700 people
- Sponsor
- Weill Medical College of Cornell University
Coronary Artery Disease
Optimizing Aspirin and Clopidogrel Therapy (BOchum CLopidogrel and Aspirin Plan)
Dual antiplatelet therapy with acetylsalicylic acid (ASA, aspirin) and clopidogrel is of great importance for treatment following coronary stenting.
- Trial name
- BOCLAplan (NCT01212302)
- Testing
- Optimizing ASA and clopidogrel treatment
- Where
- Germany
- Volunteers
- 500 people
- Sponsor
- Ruhr University of Bochum
Percutaneous Coronary Intervention
A Phase 2 Safety and Efficacy Study of PRT060128, a Novel Intravenous and Oral P2Y12 Inhibitor, in Non-Urgent PCI
This is a multi-center, randomized, double-blind, triple-dummy, clopidogrel-controlled study of IV and oral PRT060128 compared to clopidogrel in patients undergoing non-urgent (including elective) PCI.
- Trial name
- INNOVATE-PCI (NCT00751231)
- Testing
- clopidogrel, PRT060128
- Where
- 59 sites in United States, Austria and 3 more
- Volunteers
- 652 people
- Sponsor
- Portola Pharmaceuticals
Multi Vessel Coronary Artery Disease
Dual Antiplatelet Therapy in Patients With Clopidogrel Resistance Following Off-Pump Coronary Artery Bypass
Ticagrelor, a direct-acting oral P2Y12-receptor antagonist, provides greater and more consistent platelet inhibition than clopidogrel.
- Trial name
- NCT05166538
- Testing
- Ticagrelor, Clopidogrel
- Where
- South Korea
- Volunteers
- 204 people
- Sponsor
- Yonsei University
Coronary Artery Disease
Antiplatelet Response, Interval Variability & Events in Percutaneous Coronary Intervention (ARIVE-PCI) Registry
Subjects in this study have recently had or are scheduled for a percutaneous coronary intervention (PCI) as part of their normal, routine medical care. This procedure should restore the blood flow in the vessels of the heart.
- Trial name
- ARIVE-PCI (NCT01278043)
- Where
- United States
- Volunteers
- 101 people
- Sponsor
- University of Chicago
Coronary Artery Disease, Acute Coronary Syndromes
Aspirin 50mg vs 100mg Combined With P2Y12 Inhibitor After PCI
This is a randomized, open-label, active-controlled, non-inferiority clinical trial (the ASPIRE-LD trial) conducted in China. It aims to compare the efficacy and safety of low-dose aspirin (50 mg once daily) versus standard-dose…
- Conditions
- Coronary Artery Disease, Acute Coronary Syndromes, Chronic Coronary Syndrome, Percutaneous Coronary Intervention
- Trial name
- ASPIRE-LD (NCT07846462)
- Testing
- Aspirin, P2Y12 inhibitor
- Where
- China
- Volunteers
- 2,640 people
- Sponsor
- Jilin University
Ischemic Stroke, Ischemic Stroke, Acute
Tegoprazan for Prevention of Gastrointestinal Complication in Ischemic Stroke Patients on Antiplatelet Therapy (TegoStroke)
Patients with ischemic stroke commonly receive antiplatelet therapy, frequently starting as dual antiplatelet therapy, which is associated with an increased risk of gastrointestinal complications.
- Conditions
- Ischemic Stroke, Ischemic Stroke, Acute, Transient Ischemic Attack (TIA), Cerebrovascular Disease
- Trial name
- TegoStroke (NCT07687706)
- Testing
- Tegoprazan 50 mg
- Where
- 24 sites in South Korea
- Volunteers
- 1,524 people
- Sponsor
- Hanyang University Guri Hospital
Coronary Artery Disease, Coronary Thrombosis
Scripps Evaluation of Antiplatelet Therapies for Intermediate Duration With the Endeavor Stent (Seaside)
Despite the benefit of drug-eluting stents (DES) to reduce the need for repeat revascularization procedures, concerns regarding late stent thrombosis (ST) have led to recent guidelines advocating extended prescription of dual…
- Trial name
- SEASIDE (NCT00963781)
- Testing
- Medtronic Endeavor Stent, Reduced duration (6 months) DAPT
- Where
- United States
- Volunteers
- 219 people
- Sponsor
- Scripps Health
Bleeding, Thrombosis
Occurrence of Bleeding and Thrombosis During Antiplatelet Therapy in Non-cardiac Surgery
Research questions: 1. What is the absolute risk reduction for in-hospital major adverse cardiac events (MACE) associated with the use of dual anti-platelet therapy as compared with aspirin alone in this population? 2.
- Conditions
- Bleeding, Thrombosis, Cardiac Events
- Trial name
- OBTAIN (NCT01358422)
- Where
- 3 sites in Germany, Netherlands and 1 more
- Volunteers
- 830 people
- Sponsor
- European Society of Anaesthesiology
Acute Myocardial Infarction, Cardiogenic Shock
Dual Antiplatelet Therapy For Shock Patients With Acute Myocardial Infarction
Multicenter, international, randomized, placebo-controlled, double-blind trial comparing intravenous cangrelor and crushed oral ticagrelor in patients with acute myocardial infarction complicated by initial cardiogenic shock…
- Trial name
- DAPT-SHOCK-AMI (NCT03551964)
- Testing
- Cangrelor, Ticagrelor
- Where
- 29 sites in Czechia, France and 3 more
- Volunteers
- 605 people
- Sponsor
- Faculty Hospital Kralovske Vinohrady
Bleeding, Platelet Dysfunction Due to Drugs
Reversal of Dual Antiplatelet Therapy With Cold Stored Platelets
This study aims to determine whether cold-stored platelets (CSP) are equally, more effective, or uniquely effective at reversing the effect of dual antiplatelet therapy in healthy human subjects compared to…
- Conditions
- Bleeding, Platelet Dysfunction Due to Drugs, Platelet Dysfunction
- Trial name
- R-DAPT (NCT03787927)
- Testing
- Autologous Platelet Transfusion (room-temperature-stored), Autologous Platelet Transfusion (cold-stored 5 days), Autologous Platelet Transfusion (cold-stored 10 days)
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Bloodworks
Coronary Artery Disease
Short-term Dual Antiplatelet Therapy After Deployment of Bioabsorbable Polymer Everolimus-eluting Stent
To compare the clinical outcomes of P2Y12 antagonist monotherapy with aspirin plus P2Y12 antagonist following 3-month of DAPT in patients undergoing PCI with bioabsorbable polymer Everolimus-eluting stents (Synergy®)
- Trial name
- NCT03447379
- Testing
- P2Y12 antagonist monotherapy, Aspirin plus P2Y12 antagonist
- Where
- South Korea
- Volunteers
- 1,452 people
- Sponsor
- Gangnam Severance Hospital
Acute Stroke, Dual Antiplatelet Therapy
Statin and Dual Antiplatelet Therapy to Prevent Early Neurological Deterioration in Branch Atheromatous Disease
Branch atheromatous disease (BAD) has been reported to contribute to small-vessel occlusion and is associated with a higher possibility of early neurological deterioration (END).
- Conditions
- Acute Stroke, Dual Antiplatelet Therapy, Statin
- Trial name
- SATBRAD (NCT04824911)
- Testing
- Clopidogrel, Aspirin, Atorvastatin
- Where
- Taiwan
- Volunteers
- 376 people
- Sponsor
- Chang Gung Memorial Hospital